Hostname: page-component-848d4c4894-mwx4w Total loading time: 0 Render date: 2024-07-03T15:00:38.153Z Has data issue: false hasContentIssue false

P0220 - Remission in patients with psychotic disorder and treatment with risperidone of long liberation

Published online by Cambridge University Press:  16 April 2020

M. Serrano Vazquez
Affiliation:
Psychiatry Service of Juan Canalejo Hospital, A Coruna, Spain
M.C. Serrano Carton
Affiliation:
Psychiatry Service of Juan Canalejo Hospital, A Coruna, Spain
M.M. Serrano Carton
Affiliation:
Psychiatry Service of Juan Canalejo Hospital, A Coruna, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims:

To consider the different levels of remission of negative, positive or disorganization disorders, following Andreasen´s criteria in a population of Schizophrenic and Schizoaffective patients in treatment with Risperidone Consta and the relationship between levels of therapeutic fulfillment and functionality achieved.

Methods:

138 patients admitted to Acute Unit that required Risperidone Consta have been evaluated. After 6 months of treatment, 80 patients were interviewed and grouped in patients “in remission” and in “not remission”. It applied protocol with demographic data, questions about medication, disease, current status, scale for Remission (Andreasen), DAI, EEAG and WHO/DAS.

Results:

The average age was 39 years. The sample was mostly males (63.8%), singles, widowed or divorced (90%), living in a family environment (80%), with basic educational level (84%), unemployed (63.8%), they live in urban areas (71.3%). Diagnoses in order of frecuency were Schizophrenia (87.5%), Bipolar Disorder (5%), Schizoaffective disorder (2.5%), paranoia (5%). The 83.8% of patients supported Risperidone Consta during 6 months and 16.3% abandoned medication. The average time development of the disease was 12.16 years.

Conclusions:

Most of patients (80%) achieved remission. Those who achieved remission presents fewer admissions, a higher satisfaction level, a better perception of health, with significant differences. The abandon of the medication is the fundamental reason of not remission of symptoms.

Patients who got remission relate to higher performance (EEAG) and lowest values of disabilities (WHO-DAS), both in employment levels, in family and social life, with significant differences. The fulfillment and therapeutic adherence is an important factor in remission (DAI).

Type
Poster Session I: Schizophrenia and Psychosis
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.